volixibat
volixibat: developed by 1 company · 2 clinical trials tracked.
volixibat evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could volixibat → MIRM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) Primary Biliary Cholangitis; Primary Sclerosing Cholangitis | Phase 3 |
Clinical Trials (2)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis
Primary endpoint: Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Primary endpoint: Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire
Frequently asked questions
Who is developing volixibat?
volixibat is being developed by Mirum Pharmaceuticals, Inc..
How many clinical trials involve volixibat?
BioSniper tracks 2 clinical trials involving volixibat.